作者
Maciej Banach, Manfredi Rizzo, Peter P Toth, Michel Farnier, Michael H Davidson, Khalid Al-Rasadi, Wilbert S Aronow, Vasilis Athyros, Dragan M Djuric, Marat V Ezhov, Robert S Greenfield, G Kees Hovingh, Karam Kostner, Corina Serban, Daniel Lighezan, Zlatko Fras, Patrick M Moriarty, Paul Muntner, Assen Goudev, Richard Ceska, Stephen J Nicholls, Marlena Broncel, Dragana Nikolic, Daniel Pella, Raman Puri, Jacek Rysz, Nathan D Wong, Laszlo Bajnok, Steven R Jones, Kausik K Ray, Dimitri P Mikhailidis
发表日期
2015/6/3
来源
Expert opinion on drug safety
卷号
14
期号
6
页码范围
935-955
出版商
Informa Healthcare
简介
Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term ‘statin intolerance’. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 – 15% of patients.
In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to …
学术搜索中的文章
M Banach, M Rizzo, PP Toth, M Farnier, MH Davidson… - Expert opinion on drug safety, 2015